2023-2029 Global Short-acting B2 Agonists Industry Research & Trends Analysis Report

According to YH Research, the global market for Short-acting B2 Agonists should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
China Short-acting B2 Agonists market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
The United States Short-acting B2 Agonists market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
In terms of type, Albuterol segment holds a share about % in 2022 and will reach % in 2029; while in terms of application, COPD has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.
The global key manufacturers of Short-acting B2 Agonists include Bayer AG, Teva, Roche, Viatris, GSK, Cipla Limited, Johnson & Johnson and Merck, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.
Short-acting B2 agonists (SABAs) are albuterol, levalbuterol, metaproterenol, and terbutaline, and they are prescribed for bronchospasm caused by COPD, bronchial asthma, or emphysema.
This report aims to provide a comprehensive study of the global market for Short-acting B2 Agonists. Report Highlights:
(1) Global Short-acting B2 Agonists market size (sales volume & revenue), history data from 2018-2022 and forecast data from 2023 to 2029.
(2) Global Short-acting B2 Agonists market competitive situation, sales, revenue, price and market share, from 2018 to 2022.
(3) China Short-acting B2 Agonists market competitive situation, sales, revenue, price and market share, from 2018 to 2022.
(4) Global Short-acting B2 Agonists segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.
(5) Global Short-acting B2 Agonists segment by type and by application and regional segment by type and by application.
(6) Global major production regions of Short-acting B2 Agonists, capacity, production and trends.
(7) Short-acting B2 Agonists industry supply chain, upstream, midstream and downstream analysis.
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by type, covers
Albuterol
Metaproterenol
Levalbuterol
Other
Market segment by application, can be divided into
COPD
Asthma
Other
Market segment by players, this report covers
Bayer AG
Teva
Roche
Viatris
GSK
Cipla Limited
Johnson & Johnson
Merck